ABCL AbCellera Biologics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703057 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY92.1%
TTM net income YoY13.6%
TTM EPS YoY15.8%
Revenue 3-yr CAGR10.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-298.0%
Net margin-218.5%
FCF margin-48.4%
EBITDA margin-264.0%
Returns
ROE-14.6%
ROA-10.4%
ROIC (approx.)-18.2%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets29.2%
Debt / equity0.00x
Current ratio12.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-9.3%
Payout ratio—
Capex / revenue25.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $75.13M | $28.83M |
| R&D expense | $186.83M | $167.26M |
| SG&A expense | $83.23M | $85.49M |
| Operating income | -$217.10M | -$314.77M |
| Pretax income | -$177.59M | -$200.40M |
| Income tax | -$31.18M | -$37.54M |
| Net income | -$146.41M | -$162.86M |
| EBITDA | -$198.66M | -$302.23M |
| EPS (basic) | -0.49 | -0.55 |
| EPS (diluted) | -0.49 | -0.55 |
| Weighted avg. shares (diluted) | 298.71M | 294.33M |
| Balance sheet | ||
| Cash & equivalents | $128.51M | $156.32M |
| Receivables | $39.41M | $31.98M |
| Inventory | $6.34M | $0 |
| Current assets | $728.23M | $751.37M |
| Goodwill | $47.81M | $47.81M |
| Intangibles | $38.38M | $42.11M |
| Total assets | $1.36B | $1.36B |
| Current liabilities | $64.31M | $76.61M |
| Total liabilities | $390.05M | $304.47M |
| Shareholders' equity | $966.90M | $1.06B |
| Shares outstanding | 300.60M | 295.76M |
| Cash flow statement | ||
| Operating cash flow | -$131.29M | -$108.56M |
| Capital expenditure | $42.77M | $78.40M |
| Free cash flow | -$174.07M | -$186.95M |
| Investing cash flow | $87.75M | $121.41M |
| Financing cash flow | $14.08M | $12.77M |
| Depreciation & amortization | $18.44M | $12.54M |
| Stock-based compensation | $55.79M | $67.58M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.